Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH2 | P25021 | 7/20 | 0.42 |
| ▸ | HRH1 | P35367 | 7/20 | 0.42 |
| ▸ | HTR7 | P34969 | 3/20 | 0.42 |
| ▸ | HTR1A | P08908 | 1/20 | 0.42 |
| ▸ | SIGMAR1 | Q99720 | 5/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.36 |
| ▸ | HTR4 | Q13639 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.35 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26501211 | 0.89 | PAOX (0.45) | HRH2HRH1HTR7 | |
| SCHEMBL26501212 | 0.89 | PAOX (0.45) | HRH2HRH1HTR7 | |
| SCHEMBL26501232 | 0.83 | PAOX (0.45) | HRH2HRH1HTR7 | |
| SCHEMBL26501230 | 0.80 | SIGMAR1 (0.39) | HRH2HRH1SIGMAR1 | |
| SCHEMBL20314581 | 0.78 | DRD3 (0.40) | HRH2HRH1HTR7HTR1ASIGMAR1 | |
| SCHEMBL21898958 | 0.78 | SIGMAR1 (0.41) | HRH2HRH1HTR7HTR1ASIGMAR1 | |
| SCHEMBL27411228 | 0.77 | HTR7 (0.36) | HTR7HTR1ASIGMAR1MEN1KMT2A | |
| SCHEMBL470992 | 0.76 | EPHX2 (0.47) | HRH2HRH1 | |
| SCHEMBL26263692 | 0.75 | FAAH (0.34) | MEN1KMT2A | |
| SCHEMBL26972452 | 0.75 | HRH3 (0.40) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230321253-A1 | BIFUNCTIONAL COMPOUNDS AND PHARMACEUTICAL USES THEREOF | Risen (Suzhou) Pharma Tech Co., Ltd. (CN) | 2023-10-12 | — | — | US | disclosed |
| US-20230321253-A1 | BIFUNCTIONAL COMPOUNDS AND PHARMACEUTICAL USES THEREOF | Risen (Suzhou) Pharma Tech Co., Ltd. (CN) | 2023-10-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230321253-A1 | BIFUNCTIONAL COMPOUNDS AND PHARMACEUTICAL USES THEREOF | KRAS, MDM2, NRAS | HRH2 3216/4885HRH1 2655/4885HTR7 4751/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.